Syringe cracks prompt J&J Janssen recall

A production line for J&J unit Janssen's antipsychotic drug Invega Sustenna is back in operation following an investigation into cracked syringes. A 70,000-dose recall is under way.

Users are unlikely to have seen the cracks on the syringe barrel because they were covered by labels. The defect was found during routine testing at the Belgium manufacturing site. Janssen suspects that stress during label application caused the cracking.

Only 234-mg dose syringes have shown the cracking. Distribution began last March, and the recall notice was sent to distributors, pharmacists and healthcare providers in the U.S., Australia, Canada and South Korea.

- see the story
- here's the recall notice

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.